Biotherapies in large vessel vasculitis

Revue de Medecine Interne

Volumn 37, Issue 4, 2016, Pages 274-278

  Pazzola, G ^a   Muratore, F ^a   Pipitone, N ^a   Salvarani, C ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

Biological therapies; Biotherapies; Giant cell arteritis; Large vessel vasculitis; Takayasu arteritis

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; PLACEBO; PREDNISONE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT;

AGE; AORTA ARCH SYNDROME; BIOLOGICAL THERAPY; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; GENDER; GIANT CELL ARTERITIS; HUMAN; HUMORAL IMMUNE DEFICIENCY; LARGE VESSEL VASCULITIS; MULTICENTER STUDY (TOPIC); PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; SHORT SURVEY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VASCULITIS; PROCEDURES; TAKAYASU ARTERITIS;

ANTIRHEUMATIC AGENTS; BIOLOGICAL THERAPY; GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; TAKAYASU ARTERITIS;

EID: 84961204983     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2015.08.012     Document Type: Short Survey

References (52)

1. Hoffman G.S., Cid M.C., Rendt-Zagar K.E., Merkel P.A., Weyand C.M., Stone J.H., et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007, 146:621-630.
2. Seror R., Baron G., Hachulla E., Debandt M., Larroche C., Puéchal X., et al. Adalimumab for steroid sparing in patients with giant cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis 2013, 73:2074-2081.
3. Martínez-Taboada V.M., Rodríguez-Valverde V., Carreño L., López-Longo J., Figueroa M., Belzunegui J., et al. A double-blind placebo-controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008, 67:625-630.
4. Cantini F., Niccoli L., Salvarani C., Padula A., Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001, 44:2933-2935.
5. Andonopoulos A.P., Meimaris N., Daoussis D., Bounas A., Giannopoulos G. Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 2003, 62:1116.
6. Ahmed M.M., Mubashir E., Hayat S., Fowler M., Berney S.M. Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol 2007, 26:1353-1355.
7. Mukhtyar C., Guillevin L., Cid M.C., Dasgupta B., de Groot K., Gross W., et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009, 68:318-323.
8. Unizony S., Stone J.H., Stone J.R. New treatment strategies in large vessel vasculitis. Curr Opin Rheumatol 2013, 25:3-9.
9. Kötter I., Henes J.C., Wagner A.D., Loock J., Gross W.L. Does glucocorticosteroid-resistant large vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol 2012, 30(1 Suppl. 70):S114-S129.
10. Hoffman G.S., Merkel P.A., Brasington R.D., Lenschow D.J., Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004, 50:2296-2304.
11. Molloy E.S., Langford C.A., Clark T.M., Gota C.E., Hoffman G.S. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 2008, 67:1567-1569.
12. Schmidt J., Kermani T.A., Bacani A.K., Crowson C.S., Matteson E.L., Warrington K.J. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term follow-up. Arthritis Care Res (Hoboken) 2012, 64:1079-1083.
13. Clifford A., Hoffman G.S. Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies. Curr Opin Rheumatol 2014, 26:7-15.
14. Comarmond C., Plaisier E., Dahan K., Mirault T., Emmerich J., Amoura Z., et al. Anti-TNFα in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmun Rev 2012, 11:678-684.
15. Weyand C.M., Hicok K.C., Hunder G.G., Goronzy J.J. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994, 121:484-491.
16. Emilie D., Liozon E., Crevon M.C., Lavignac C., Portier A., Liozon F., et al. Production of interleukin 6 by granulomas of giant cell arteritis. Hum Immunol 1994, 39:17-24.
17. García-Martínez A., Hernández-Rodríguez J., Espígol-Frigolé G., Prieto-González S., Butjosa M., Segarra M., et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term follow-up of patients with giant cell arteritis. Arthritis Care Res (Hoboken) 2010, 62:835-841.
18. Weyand C.M., Fulbright J.W., Hunder G.G., Evans J.M., Goronzy J.J. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000, 43:1041-1048.
19. Nishimoto N., Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006, 2:619-626.
20. Sciascia S., Rossi D., Roccatello D. Interleukin 6 blockade as steroid sparing treatment for 2 patients with giant cell arteritis. J Rheumatol 2011, 38:2080-2081.
21. Seitz M., Reichenbach S., Bonel H.M., Adler S., Wermelinger F., Villiger P.M. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011, 141:w13156.
22. Salvarani C., Magnani L., Catanoso M., Pipitone N., Versari A., Dardani L., et al. Tocilizumab: a novel therapy for patients with large vessel vasculitis. Rheumatology (Oxford) 2012, 51:151-156.
23. Beyer C., Axmann R., Sahinbegovic E., Distler J.H., Manger B., Schett G., et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis 2011, 70:1874-1875.
24. Vinit J., Bielefeld P., Muller G., Besancenot J.-F. Efficacy of tocilizumab in refractory giant cell arteritis. Joint Bone Spine 2012, 79:317-318.
25. Unizony S., Arias-Urdaneta L., Miloslavsky E., Arvikar S., Khosroshahi A., Keroack B., et al. Tocilizumab for the treatment of large vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 2012, 64:1720-1729.
26. Besada E., Nossent J.C. Ultrasonographic resolution of the vessel wall oedema with modest clinical improvement in a large vessel vasculitis patient treated with tocilizumab. Clin Rheumatol 2012, 31:1263-1265.
27. Kieffer P., Hinschberger O., Ciobanu E., Jaeger-Bizet F., Drabo A., Mostoufizadeh T., et al. Clinical and biological efficacy of tocilizumab in giant cell arteritis: report of three patients and literature review. Rev Med Interne 2014, 35:56-59.
28. Oliveira F., Butendieck R.R., Ginsburg W.W., Parikh K., Abril A. Tocilizumab, an effective treatment for relapsing giant cell arteritis. Clin Exp Rheumatol 2014, 32(3 Suppl. 82):S76-S78.
29. Işik M., Kiliç L., Doğan I., Calgüneri M. Tocilizumab for giant cell arteritis: an amazing result. Rheumatol Int 2013, 33:2961-2962.
30. Christidis D., Jain S., Das Gupta B. Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement. BMJ Case Rep 2011, 30:2011.
31. Lurati A., Bertani L., Re K.A., Marrazza M., Bompane D., Scarpellini M. Successful treatment of a patient with giant cell vasculitis (Horton arteritis) with tocilizumab a humanized anti-interleukin-6 receptor antibody. Case Rep Rheumatol 2012, 2012:639612.
32. Pazzola G., Padovano I., Boiardi L., Versari A., Pipitone N., Catanoso M., et al. Tocilizumab in glucocorticoid-naïve large vessel vasculitis. Clin Exp Rheumatol 2013, 31(1 Suppl. 75):S59-S61.
33. Hernández-Rodríguez J., Segarra M., Vilardell C., Sánchez M., García-Martínez A., Esteban M.J., et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003, 107:2428-2434.
34. Unizony S.H., Dasgupta B., Fisheleva E., Rowell L., Schett G., Spiera R., et al. Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol 2013, 2013:912562.
35. Nishimoto N., Nakahara H., Yoshio-Hoshino N., Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2008, 58:1197-1200.
36. Salvarani C., Magnani L., Catanoso M.G., Pipitone N., Versari A., Dardani L., et al. Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-α blockers. Clin Exp Rheumatol 2012, 30(1 Suppl. 70):S90-S93. [42].
37. Bredemeier M., Rocha C.M., Barbosa M.V., Pitrez E.H. One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab. Clin Exp Rheumatol 2012, 30(1 Suppl. 70):S98-S100.
38. Bravo Mancheño B., Perin F., Guez Vázquez Del Rey M.D.M.R., García Sánchez A., Alcázar Romero P.P. Successful tocilizumab treatment in a child with refractory Takayasu arteritis. Pediatrics 2012, 130:e1720-e1724.
39. Xenitidis T., Horger M., Zeh G., Kanz L., Henes J.C. Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis. Rheumatology (Oxford) 2013, 52:1729-1731.
40. Abisror N., Mekinian A., Lavigne C., Vandenhende M.-A., Soussan M., Fain O. Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review. Autoimmun Rev 2013, 12:1143-1149.
41. Inder S.J., Bobryshev Y.V., Cherian S.M., Wang A.Y., Lord R.S., Masuda K., et al. Immunophenotypic analysis of the aortic wall in Takayasu's arteritis: involvement of lymphocytes, dendritic cells and granulocytes in immuno-inflammatory reactions. Cardiovasc Surg 2000, 8:141-148.
42. Hoyer B.F., Mumtaz I.M., Loddenkemper K., Bruns A., Sengler C., Hermann K.-G., et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 2012, 71:75-79.
43. Osman M., Pagnoux C., Dryden D.M., Storie D., Yacyshyn E. The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis. PLoS One 2014, 9:e115026.
44. Kaneko U., Kishi T., Kikuchi M., Hara R., Shinoki T., Miyamae T., et al. Infliximab therapy for three adolescent patients with refractory Takayasu's arteritis [Japanese]. Nihon Rinsho Meneki Gakkai Kaishi 2010, 33:317-323.
45. Buonuomo P.S., Bracaglia C., Campana A., Insalaco A., Pardeo M., Cortis E. Infliximab therapy in pediatric Takayasu's arteritis: report of two cases. Rheumatol Int 2011, 31:93-95.
46. Mekinian A., Neel A., Sibilia J., Cohen P., Connault J., Lambert M., et al. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology 2012, 51:882-886.
47. Canas C., Izquierdo J.H., Bonilla F. Efficacy of anti-interleukin-6 receptor antibody (tocilizumab) in Colombian patients with Takayasu arteritis. Ann Rheum Dis 2012, 71:681.
48. Galarza C., Valencia D., Tobon G.J., Zurita L., Mantilla R.D., Pineda-Tamayo R., et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?. Clin Rev Allergy Immunol 2008, 34:124-128.
49. Della Rossa A., Tavoni A., Merlini G., Baldini C., Sebastiani M., Lombardi M., et al. Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent?. Rheumatology (Oxford) 2005, 44:1074-1075.
50. Karageorgaki Z.T., Mavragani C.P., Papathanasiou M.A., Skopouli F.N. Infliximab in Takayasu arteritis: a safe alternative?. Clin Rheumatol 2007, 26:984-987.
51. Filocamo G., Buoncompagni A., Viola S., Loy A., Malattia C., Ravelli A., et al. Treatment of Takayasu's arteritis with tumor necrosis factor antagonists. J Pediatr 2008, 153:432-434.
52. Nunes G., Neves F.S., Melo F.M., de Castro G.R.W., Zimmermann A.F., Pereira I.A. Takayasu arteritis: anti-TNF therapy in a Brazilian setting. Rev Bras Reumatol 2010, 50:291-298.